This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-17 and is reviewed periodically as new material appears.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Tuberculin, known in its modern form as purified protein derivative (PPD), is a combination of proteins that are used in the diagnosis of tuberculosis by injection into the skin. Common side effects include redness, itchiness (pruritus), and pain at the site of injection. Allergic reactions may occasionally occur. Use is safe in pregnancy. The original tuberculin, a glycerin extract of Mycobacterium tuberculosis, was discovered in 1890 by Robert Koch. Koch, best known for his work on the etiology (cause, origin) of tuberculosis (TB), laid down various rigorous guidelines that aided the establishment between a pathogen and the specific disease that followed that were later named Koch's postulates. Although he initially believed it would cure tuberculosis, this was later disproved. PPD was invented in 1934 by Florence B. Seibert, greatly improving the reliability of the skin test over Koch's extract. PPD is on the World Health Organization's List of Essential Medicines.
Naturally occurring europium (63Eu) is composed of two isotopes, 151Eu and 153Eu, with 153Eu being the more abundant (52.2% natural abundance). While 153Eu is observationally stable, 151Eu was found in 2007 to be unstable and undergo alpha decay; its measured half-life of 4.6 × 1018 years corresponds to 1 alpha decay per two minutes per kilogram of natural europium, so for practical purposes it can be considered stable. Besides the natural radioisotope 151Eu, artificial radioisotopes from 130Eu to 170Eu have been made, with the most stable being 150Eu with a half-life of 36.9 years, 152Eu with a half-life of 13.517 years, 154Eu with a half-life of 8.592 years, and 155Eu with a half-life of 4.742 years. All the others have half-lives shorter than 100 days, with the majority shorter than 3 minutes. This element also has 27 metastable isomers, with the most stable being 150mEu (12.8 hours), 152m1Eu (9.3116 hours) and 152m5Eu (96 minutes). The primary decay mode for isotopes lighter than 153Eu is electron capture to samarium isotopes, and the primary mode for heavier isotopes is beta minus decay to gadolinium isotopes. 152Eu and 154Eu can decay either way, as can 150mEu (meta state only).
Computational neuroscientists show that people with higher intelligence scores in HCP cognitive tests took more time to solve difficult problems and that their higher synchrony between brain areas allowed for better integration of evidence (or progress) from preceding working memory sub-problem processing. Reducing synchrony in "avatar" simulations, that were adjusted and tuned towards personalization, "led decision-making circuits to quickly jump to conclusions". Their codified results may be useful for an understanding of cognition to replicate or imitate in bio-inspired computing. Researchers report trends in reasons for HPV vaccine hesitancy during 2010–20. 24 May Scientists show how gene 'FAAH'-related disruption via genetic or epigenome editing can enable pain insensitivity (see also 10 March 2021). Their analyses, mainly about long non-coding RNA 'FAAH-OUT', following from decade-long study of a woman who can't feel pain or anxiety, could also enable novel therapeutic developments against other neurological problems. One of the first empirical studies on what real users are shown during their typical use of popular Web search engines interprets its results to show that choices for unreliable news sources for their queries are driven primarily by users' own choices and less by the engine's algorithms. The Web scientists link their findings to the concept of filter bubbles which emphasizes the role of design- and personalization algorithms.
The government of Nkrumah was subsequently overthrown in a coup by the Ghana Armed Forces, codenamed "Operation Cold Chop". This occurred while Nkrumah was abroad with Zhou Enlai in the People's Republic of China, on a mission to Hanoi, Vietnam, to help end the Vietnam War. The coup took place on 24 February 1966, led by Colonel Emmanuel Kwasi Kotoka and Brigadier Akwasi Afrifa. The National Liberation Council was formed, chaired by Lieutenant General Joseph A. Ankrah. A series of alternating military and civilian governments, mostly affected by economic instabilities, ruled Ghana from 1966, ending with the ascent to power of Flight Lieutenant Jerry John Rawlings of the Provisional National Defence Council in 1981. These changes resulted in the suspension of the constitution in 1981 and the banning of political parties. The economy declined, so Rawlings negotiated a structural adjustment plan, changing some economic policies, and growth recovered during the 1980s. A new constitution restoring multi-party system politics was promulgated in the presidential election of 1992, in which Rawlings was elected, and again in the general election of 1996. In a tribal war in Northern Ghana in 1994, between the Konkomba and other ethnic groups, including the Nanumba, Dagomba and Gonja, between 1,000 and 2,000 people were killed and 150,000 people were displaced.
Sources: en.wikipedia.org
=== International Food Safety Authorities Network (INFOSAN) === The International Food Safety Authorities Network (INFOSAN) is a joint program of the WHO and FAO. INFOSAN has been connecting national authorities from around the globe since 2004, with the goal of preventing the international spread of contaminated food and foodborne disease and strengthening food safety systems globally. This is done by:
=== Controlling pore shape === Additives can prove highly useful and versatile in changing the morphology of pores. These work by affecting the growth kinetics and microstructure of the ice in addition to the topology of the ice-water interface. Some additives work by altering the phase diagram of the solvent. For example, water and NaCl have a eutectic phase diagram. When NaCl is added into a freeze-casting suspension, the solid ice phase and liquid regions are separated by a zone where both solids and liquids can coexist. This briny region is removed during sublimation, but its existence has a strong effect on the microstructure of the porous ceramic. Other additives work by either altering the interfacial surface energies between the solid/liquid and particle/liquid, changing the viscosity of the suspension, or the degree of undercooling in the system. Studies have been done with glycerol, sucrose, ethanol, acetic acid and more.
=== Distillation columns === The concept of theoretical plates in designing distillation processes has been discussed in many reference texts. Any physical device that provides good contact between the vapor and liquid phases present in industrial-scale distillation columns or laboratory-scale glassware distillation columns constitutes a "plate" or "tray". Since an actual, physical plate can never be a 100% efficient equilibrium stage, the number of actual plates is more than the required theoretical plates.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.